---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-059393"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2026-05-12T20:11:00+00:00"
generated_at: "2026-05-12T20:58:19.521064+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q1 revenue $19.1M (+3% YoY); net loss $12.3M; reiterates FY2026 revenue growth at least 8%

## Summary
- Revenue $19.1M (+3% YoY), unit growth 13%; European revenue up 41% YoY.
- Net loss $12.3M vs $11.3M prior year; operating loss $10.5M.
- Gross margin 65.7% (down from 67.6%) on higher excess/obsolete inventory charge.
- Reiterated FY2026 revenue growth at least 8% over FY2025; Q2 2026 expected ~$20.0M.
- U.S. commercial launch of OviTex LTR (April 1) and board refreshment effective June 9, 2026.

## SEC filing metadata
- accession: 0001104659-26-059393
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2026-05-12T20:11:00+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465926059393/0001104659-26-059393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465926059393/tm2614218d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-059393
- JSON: https://secwatch.observer/filing/0001104659-26-059393.json
- Plain text: https://secwatch.observer/filing/0001104659-26-059393.txt

## Key facts
- Earnings Releases
  TELA Bio, Inc. reported first quarter ended March 31, 2026 results: revenue $19.1 million, net income Net loss was $12.3 million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2026
  - Revenue: $19.1 million
  - Net income: Net loss was $12.3 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: at the conclusion of the 2026 Annual Meeting on June 9, 2026; · Noted the U.S. commercial organization is fully staffed at planned 2026 levels; · Delivered revenue of $19.1 million in the first quarter of 2026, representing growth of 3% over the prior year period; · Accelerated European revenue growth to 41% over the prior year period, with continued
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465926059393/0001104659-26-059393-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.